You just read:

DelMar Pharmaceuticals Announces Completion of First Site Initiation Visit for STAR-3 Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM

News provided by

DelMar Pharmaceuticals, Inc.

Jul 18, 2017, 08:30 ET